Skip to content

RoActemra 162 mg solution for injection in pre-filled pen.

DRUG5 trials

Sponsors

Karolinska University Hospital, Abbvie Deutschland GmbH & Co. KG, Centre Hospitalier Universitaire De Dijon, IRCCS Istituto Giannina Gaslini, Assistance Publique Hopitaux De Paris

Conditions

Giant Cell ArteritisJuvenile idiopathic arthritisPatients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.Patients with histologically (or via cytology) confirmed cancer that develop arthritis secondary to treatment with immune checkpoint inhibitors.juvenile idiopathic arthritis

Phase 2

Phase 3

Phase 4